Early research (Phase 1)Study completedNCT01220570
What this trial is testing
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 63